MRKH Syndrome and DNA Testing: Can a Genetic Test Detect It?

Mayer-Rokitansky-Küster-Hauser syndrome, usually shortened to MRKH syndrome, is a rare congenital difference affecting the development of the female reproductive system. It is mainly characterised by the absence or incomplete development of the uterus, cervix and upper part of the vagina.

Because MRKH affects reproductive anatomy, it often raises questions about genetics. Can an MRKH syndrome DNA test identify the condition? Can a genetic result explain why it developed? Could MRKH cause an ancestry or relationship test to report an unexpected result for the sex chromosomes?

Answering these questions requires a clear distinction between several very different types of examination. A consumer ancestry test, a paternity test, a chromosome analysis and clinical genetic sequencing do not examine the same features and cannot be used for the same purpose.

What is MRKH syndrome?

MRKH syndrome develops before birth, during the formation of the reproductive system.

During embryonic development, structures known as the Müllerian ducts normally develop into the uterus, cervix, fallopian tubes and upper part of the vagina. In people with MRKH, these structures do not develop fully.

People with classic MRKH syndrome generally have:

• external genitalia with a typical female appearance;

• ovaries that are present and functional in most cases;

• normal breast development and other secondary sexual characteristics during puberty;

• a typically female chromosome pattern, written as 46,XX;

• an absent or underdeveloped uterus, cervix and upper vagina.

The condition is most frequently discovered during adolescence when periods do not begin. This is known medically as primary amenorrhoea.

MRKH syndrome is estimated to affect approximately one in every 4,500 to 5,000 female births.

The two main types of MRKH syndrome

Doctors generally distinguish between two forms of the condition.

MRKH type I mainly affects the uterus, cervix and upper vagina. It is sometimes described as isolated uterovaginal aplasia.

MRKH type II includes the same reproductive differences but is accompanied by other congenital anomalies. These may affect:

• the kidneys or urinary tract;

• the spine or other parts of the skeleton;

• hearing;

• more rarely, the heart.

Identifying the type of MRKH can help the medical team decide which additional examinations are appropriate and whether referral to clinical genetics may be useful.

What is the connection between MRKH syndrome and DNA?

DNA contains the biological instructions involved in the development and functioning of the human body. However, the process that turns genetic instructions into fully formed organs is highly complex.

In classic MRKH syndrome, the sex chromosomes are usually XX. The condition is therefore not normally caused by a missing X chromosome, an unexpected Y chromosome or an “undetermined” chromosome pattern.

The main difference occurs during the embryonic development of the internal reproductive structures.

The ovaries develop from different embryonic tissue from the uterus and upper vagina. They can therefore develop and function normally even when the Müllerian structures have not formed completely.

As a result, a person may have:

• a 46,XX karyotype;

• functioning ovaries;

• normal hormone production;

• typical pubertal development;

• no fully developed uterus.

This is an important distinction. Sex chromosomes provide valuable genetic information, but they do not describe every aspect of a person’s reproductive anatomy.

Is MRKH syndrome a hereditary genetic condition?

There is currently no single definitive answer.

Most cases of MRKH syndrome appear to be sporadic, meaning that no other affected person is known within the family. Familial cases have nevertheless been documented, suggesting that genetic factors contribute to the condition in at least some individuals.

Researchers have investigated several chromosome regions and genes involved in the embryonic development of the Müllerian ducts and urinary system.

The genetic findings most frequently studied include:

• the 17q12 chromosome region;

• the 16p11.2 chromosome region;

• LHX1;

• HNF1B;

• TBX6;

• GREB1L;

• PAX8;

• genes from the HOXA family;

• WNT4 in particular clinical presentations.

These findings do not establish a single cause for all cases.

MRKH syndrome is likely to represent a group of biologically different developmental conditions. Depending on the individual, its occurrence may involve:

• a variation in one gene;

• several genetic variations acting together;

• a deletion or duplication of chromosome material;

• a combination of genetic, developmental and other biological factors.

There is no single “MRKH gene”

No simple genetic test looking for one mutation can currently confirm or exclude every case of MRKH syndrome.

The recurrent chromosome changes identified by researchers are found in only a minority of affected people. Even after detailed clinical genetic testing, many patients do not receive a precise molecular explanation.

A negative genetic result does not mean that the clinical diagnosis is incorrect. It means that the analysis did not identify a currently recognised genetic cause.

There are several possible reasons:

• the relevant gene may not yet be known;

• the causal variation may lie in a region not covered by the test;

• several variations may be involved;

• the condition may result from a more complex developmental mechanism;

• the available evidence may not be sufficient to classify a detected variation as disease-causing.

Can a consumer DNA test diagnose MRKH syndrome?

No. A consumer DNA test cannot diagnose MRKH syndrome.

Tests sold for ancestry research, relative matching or biological relationship testing examine selected genetic markers. Their purpose is not to evaluate the development of the uterus, cervix or vagina.

They also do not usually examine all the genes and chromosome regions that could potentially contribute to MRKH.

The diagnosis of MRKH depends primarily on medical assessment and imaging rather than on an online DNA kit.

How the main tests differ

Type of test	What it examines	Relevance to MRKH syndrome
Paternity or relationship DNA test	Genetic markers shared between participants	Cannot diagnose MRKH
Ancestry DNA test	Genetic variations compared with populations and database matches	Can explore ancestry but cannot identify MRKH
Y-chromosome test	Markers passed through a direct paternal line	Does not test for MRKH
Karyotype	The number and general structure of the chromosomes	Helps confirm a 46,XX pattern and exclude some alternative diagnoses
Chromosomal microarray	Small deletions or duplications of genetic material	May be considered in selected clinical cases
Gene panel	Variations in a predefined group of genes	May investigate suspected genetic causes but cannot detect every case
Exome or genome sequencing	A broad selection of coding regions or the wider genome	May provide an explanation in some cases, with no guarantee of a result
Pelvic ultrasound	The anatomy of the internal reproductive organs	Important in the initial assessment
Pelvic MRI	Detailed internal reproductive anatomy	One of the main examinations used to confirm uterovaginal aplasia

A saliva sample can be used to obtain DNA for many different analyses. However, the sample itself does not determine what the test can detect. The laboratory method and the regions analysed are what matter.

Which examinations are used to diagnose MRKH syndrome in the UK?

In the United Kingdom, the diagnostic process usually begins after a young person consults a GP or another healthcare professional because periods have not started.

The patient may then be referred to a specialist gynaecology, adolescent gynaecology or differences in reproductive development service.

Depending on the clinical situation, the assessment may include:

• a review of the person’s medical and family history;

• a clinical examination;

• pelvic ultrasound;

• pelvic MRI;

• blood tests to assess hormone levels;

• chromosome testing or a karyotype;

• examination of the kidneys and urinary tract;

• assessment of the skeleton, hearing or heart when associated differences are suspected.

Specialist NHS services may use MRI to examine the reproductive anatomy in detail, together with hormonal blood tests and, when necessary, a chromosome test. More information is available through the NHS specialist resource on MRKH syndrome.

Why is a karyotype important?

A karyotype examines the number and overall structure of a person’s chromosomes.

In a typical case of MRKH syndrome, it usually shows 46 chromosomes with an XX sex-chromosome pattern.

This helps doctors distinguish MRKH from other conditions that can also cause primary amenorrhoea, a shorter vagina or an apparently absent uterus.

A karyotype does not show the detailed anatomy of the uterus. It is therefore used alongside imaging and clinical assessment, not as a replacement for them.

When might more detailed genetic testing be considered?

A clinical genetics assessment may be more relevant when:

• kidney, skeletal, hearing or cardiac differences are also present;

• several members of the same family have uterine or reproductive anomalies;

• the karyotype is unusual;

• the clinical presentation does not fit classic MRKH;

• previous genetic testing has identified a chromosome variation;

• the patient wants to discuss possible genetic implications for future parenthood.

A clinical geneticist may consider a chromosomal microarray, a targeted gene panel, exome sequencing or another analysis. The choice depends on the individual’s medical history and examination findings.

Does an “undetermined chromosomal sex” result indicate MRKH syndrome?

No. A result stating that chromosomal sex could not be determined does not establish a diagnosis of MRKH syndrome.

An inconclusive result can have several explanations, including:

• insufficient usable DNA;

• a poor-quality or contaminated sample;

• degraded genetic material;

• a technical failure;

• limitations in the laboratory’s algorithm;

• incomplete coverage of the X or Y chromosomes;

• mosaicism, in which not all cells have the same chromosome pattern;

• an uncommon sex-chromosome variation;

• a difference in sex development unrelated to MRKH.

The first step is to identify exactly which test produced the result.

A prenatal screening test, ancestry test, relationship test and medical karyotype analyse different genetic material and apply different interpretation methods. The wording “undetermined” may therefore have a different meaning in each report.

It may indicate a technical limitation rather than a biological anomaly.

For this reason, an unexpected result should never be interpreted from a dashboard summary alone. The complete report, the methodology and the laboratory’s limitations must be considered.

Our guide to reading and interpreting DNA test results explains why conclusions must always be understood in relation to the exact test performed.

Can prenatal screening detect MRKH syndrome?

Routine non-invasive prenatal testing, or NIPT, is not designed to diagnose MRKH syndrome.

NIPT analyses fragments of placental DNA circulating in the pregnant person’s blood. It is mainly used to estimate the likelihood of certain chromosome conditions, particularly trisomies 21, 18 and 13.

Some NIPT services also analyse sex-chromosome material. However, this still does not assess whether the fetal uterus or Müllerian ducts are developing normally.

NIPT is a screening test rather than a definitive diagnostic examination. A low-risk, high-risk or inconclusive result must be interpreted according to the conditions being screened and may require further medical testing.

Why can MRKH be confused with other genetic or developmental conditions?

Several differences in sex development can initially appear similar because they may involve primary amenorrhoea, a short vagina or the absence of a clearly visible uterus.

Their biological causes are nevertheless different.

Classic MRKH syndrome

In classic MRKH syndrome:

• the karyotype is normally 46,XX;

• the ovaries are generally present;

• ovarian hormone production is usually normal;

• the uterus, cervix and upper vagina are absent or underdeveloped;

• secondary sexual development normally occurs during puberty.

Complete androgen insensitivity syndrome

In complete androgen insensitivity syndrome, or CAIS:

• the karyotype is 46,XY;

• internal testes are present rather than ovaries;

• the body does not respond normally to androgen hormones;

• the uterus is absent;

• external genitalia usually have a female appearance;

• breast development generally occurs during puberty.

A chromosome result showing 46,XX is therefore an important element in distinguishing classic MRKH syndrome from CAIS.

However, the karyotype is only one part of the assessment. Hormone tests, imaging and specialist examination are also required.

46,XY complete gonadal dysgenesis

In 46,XY complete gonadal dysgenesis, sometimes called Swyer syndrome:

• the karyotype is 46,XY;

• the gonads do not develop into functioning testes;

• the external genitalia usually appear female;

• spontaneous puberty may be incomplete or absent;

• primary amenorrhoea is common;

• a uterus is usually present because functioning testes did not produce the hormone that would normally suppress Müllerian development.

This differs from MRKH, in which the uterus is absent or underdeveloped despite a typical 46,XX chromosome pattern and normally functioning ovaries.

A case report published in 2020 described a 16-year-old with a female appearance whose commercial genetic test unexpectedly indicated an XY chromosome pattern.

Medical investigations subsequently identified complete 46,XY gonadal dysgenesis.

The case did not involve MRKH syndrome. It demonstrates that a consumer test may occasionally reveal unexpected information without being able to explain its medical significance.

Any such finding requires confirmation through a clinical laboratory.

Does MRKH syndrome affect ancestry or relationship DNA testing?

In a classic case, it should not.

A person with MRKH has nuclear DNA and generally has a standard 46,XX chromosome pattern. The condition does not, by itself, prevent the laboratory from carrying out:

• a paternity test;

• a maternity test;

• a siblingship test;

• a grandparentage test;

• an avuncular test;

• an autosomal ancestry test;

• mitochondrial DNA analysis.

Relationship tests compare genetic markers in cells collected from the mouth or another biological sample. The analysis does not depend on whether the participant has a uterus.

A person with MRKH can therefore take an ancestry DNA test or participate in a relationship analysis under the same general conditions as another participant.

The correct test must still be selected for the question being asked.

For example, a Y-chromosome test compares genetic markers carried on the Y chromosome. It is used to investigate a direct paternal line between participants who carry Y-chromosome material. It cannot investigate the cause of MRKH syndrome in a person with a typical 46,XX karyotype.

MRKH syndrome, ovaries and the transmission of DNA to a child

The absence of a functional uterus generally means that a person with MRKH cannot carry a pregnancy.

It does not automatically mean that the ovaries cannot produce eggs.

When the ovaries are functioning, the eggs contain half of the person’s genetic material. It may therefore be possible to have a genetically related child through assisted reproduction.

Potential routes to parenthood can include:

• IVF using the person’s own eggs;

• gestational surrogacy;

• adoption;

• in highly selected circumstances, participation in developing uterine-transplant programmes.

These options are not equally available to every patient.

Access depends on:

• ovarian function;

• age and overall health;

• the feasibility of egg retrieval;

• the availability and funding of fertility treatment;

• the rules of the fertility clinic;

• the legal framework;

• the individual’s personal choices.

IVF and surrogacy in the United Kingdom

Surrogacy is legal in the United Kingdom, but the arrangement is not legally enforceable. The surrogate is initially recognised as the child’s legal parent, and the intended parent or parents normally need to apply for a parental order after the birth.

Only reasonable expenses may be paid to a surrogate in the UK. Anyone considering this route should obtain specialist medical and legal advice before starting treatment.

NHS funding for IVF and related treatment can also vary between areas. Eligibility should be discussed with the specialist fertility team and the relevant local NHS commissioner.

What about uterine transplantation?

Uterine transplantation is a developing field that may allow selected patients without a uterus to carry a pregnancy.

The procedure involves major surgery, IVF and treatment with immunosuppressive medication. It should not be presented as a routine or widely accessible treatment.

It remains limited to highly specialised programmes and carefully selected patients.

Can MRKH syndrome be passed on to a child?

A general inheritance risk cannot currently be calculated for every person with MRKH syndrome.

In many cases, no specific genetic cause is identified. Without an established molecular diagnosis, it is not possible to provide a precise recurrence percentage.

When a potentially causal chromosome or gene variation has been found, a clinical geneticist can assess:

• how the variation may be inherited;

• whether it has been seen in other family members;

• whether it is associated with kidney or other developmental anomalies;

• whether testing relatives may be appropriate;

• what the finding may mean for future children.

Even when a genetic variation is identified, the effect may not be the same in every person who carries it. This is known as variable expression or incomplete penetrance.

Genetic counselling is therefore more useful than relying on a general statement that MRKH is either hereditary or non-hereditary.

When is a clinical genetics consultation appropriate?

A referral to clinical genetics may be particularly useful when:

• MRKH is accompanied by a kidney anomaly;

• skeletal, hearing or cardiac differences are present;

• more than one person in the family has uterine or reproductive anomalies;

• a previous karyotype produced an unusual result;

• a consumer DNA test reported unexpected sex-chromosome information;

• the patient wants to understand the potential inheritance implications;

• a genetically related child is being considered;

• the diagnosis remains uncertain;

• the clinical features suggest another difference in sex development.

The geneticist can review the medical history, construct a family tree and examine previous reports.

They can then decide whether further analysis is likely to provide meaningful information. More testing is not always useful, particularly when the result would not change medical care or counselling.

What should you do after an unusual DNA result?

An unexpected or inconclusive genetic result should not be interpreted in isolation.

A cautious approach involves the following steps.

1. Identify the exact test

Confirm whether it was:

• an ancestry test;

• a health-trait test;

• a prenatal screening test;

• a relationship test;

• a chromosome test;

• a medical sequencing analysis.

2. Obtain the complete laboratory report

A short online summary may omit:

• quality-control information;

• the markers analysed;

• the reporting threshold;

• the laboratory’s limitations;

• reasons for an inconclusive result.

3. Ask what genetic regions were examined

A test may analyse only a small number of positions on the X and Y chromosomes. That is not equivalent to a full karyotype or clinical chromosome analysis.

4. Do not diagnose MRKH from the result

MRKH is an anatomical and developmental diagnosis. A consumer DNA result cannot establish the presence or absence of a uterus.

5. Speak to an appropriate healthcare professional

Depending on the finding, this may be:

• a GP;

• a gynaecologist;

• an endocrinologist;

• a clinical geneticist;

• a specialist differences in reproductive development team.

6. Confirm the finding clinically when necessary

The medical team may recommend:

• repeat sampling;

• a clinical karyotype;

• chromosomal microarray testing;

• hormone tests;

• ultrasound;

• MRI;

• targeted genetic analysis.

Why laboratory quality is not enough on its own

A laboratory may perform an analysis accurately while the test itself remains unsuitable for the question being asked.

For example, an ancestry test can accurately identify the markers included on its genotyping chip. That does not make it a validated diagnostic test for MRKH or another reproductive-development condition.

Three separate factors must be considered:

1. Analytical validity: Did the laboratory measure the selected markers correctly?

2. Clinical validity: Is the result reliably associated with the condition being investigated?

3. Clinical utility: Does the result provide information that can guide medical care or decision-making?

Laboratory accreditation is an important quality indicator, but it does not turn an ancestry or relationship test into a medical examination.

Our guide to DNA test accreditation and reliability explains how laboratory standards, sample collection and test purpose affect the value of a result.

Conclusion: DNA can provide clues, but it cannot replace an MRKH diagnosis

MRKH syndrome is usually associated with a 46,XX karyotype, functioning ovaries and typical pubertal development, despite the absence or incomplete development of the uterus, cervix and upper vagina.

Research indicates that genetic factors probably contribute to some cases. However, no single gene or chromosome variation explains the condition in every affected person.

A consumer DNA test cannot diagnose or exclude MRKH syndrome. Diagnosis relies primarily on clinical evaluation, pelvic imaging, hormone testing and chromosome analysis where appropriate.

More detailed genetic testing may be useful when other congenital anomalies are present, several relatives are affected or the clinical presentation is unusual. Even then, the analysis may not identify a clear cause.

When a test reports an unexpected or undetermined sex-chromosome result, the first priority is to establish which test was performed and whether the result requires clinical confirmation.

An inconclusive DNA result is not a diagnosis. It does not automatically indicate MRKH syndrome or any other chromosome variation.

Does MRKH syndrome mean that a person is genetically male?

No. People with classic MRKH syndrome normally have a 46,XX karyotype.

The absence or incomplete development of the uterus results from a difference in embryonic development. It does not usually indicate the presence of a Y chromosome.

Can a saliva test detect MRKH syndrome?

Saliva can provide DNA for laboratory analysis, but the sample type does not determine which condition can be detected.

An ancestry or relationship test using saliva cannot diagnose MRKH. A clinical genetic analysis may use saliva or blood, but it must be selected and interpreted within an appropriate medical pathway.

Is there a specific genetic test for MRKH syndrome?

There is no single genetic test that detects every case.

Clinical testing may look for chromosome deletions, duplications or variations in candidate genes. However, many people with confirmed MRKH do not receive a precise genetic explanation.

Does an undetermined chromosomal-sex result indicate MRKH?

No.

An inconclusive result may be caused by insufficient DNA, sample quality, technical limitations, mosaicism or another chromosome variation. Classic MRKH is normally associated with an identifiable 46,XX karyotype.

Can MRKH syndrome affect a paternity test?

In principle, no.

Paternity testing compares genetic markers between a child and an alleged parent. The presence or absence of a uterus has no role in that comparison.

Can a person with MRKH take an ancestry DNA test?

Yes. Classic MRKH does not prevent ancestry testing.

The test may provide information about population ancestry and genetic matches, but it cannot explain or diagnose the reproductive condition.

Can a person with MRKH have a genetically related child?

Potentially, yes.

When functioning ovaries produce viable eggs, IVF may allow the creation of embryos using the person’s genetic material. The available routes to parenthood depend on the individual’s health, access to fertility treatment and the applicable UK legal framework.